Bolus Plus Infusion Remains Predominant Mode of GP IIB/IIIA Utilization: A 2015 Us Hospital Purchasing Study

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.03.138
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Preparation and Pharmacological Evaluation of Novel Glycoprotein (Gp) IIb/IIIa Antagonists. 2. Condensed Heterocyclic Derivatives.

Chemical and Pharmaceutical Bulletin
MedicineDrug DiscoveryChemistry
1999English

Glycoprotein IIb/IIIa Induced Coronary Thrombolysis

Heart
2002English

Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-Peptidic, GP IIb/IIIa Receptor Antagonist Following Multiple Oral Administrations of a Prodrug Form

Thrombosis and Haemostasis
Hematology
1998English

Off-Target Effects of Glycoprotein IIb/IIIa Receptor Inhibitors

Cardiology Journal
MedicineCardiovascular MedicineCardiology
2014English

Platelet Inhibition After Glycoprotein IIb/IIIa Inhibitor Therapy

Circulation
Cardiovascular MedicinePhysiologyCardiology
2001English

Altered Dopamine Responses to Monetary Rewards in Female Fibromyalgia Patients With and Without Depression: A [11C]Raclopride Bolus-Plus-Infusion PET Study

Psychotherapy and Psychosomatics
MedicineClinical PsychologyPsychiatryApplied PsychologyMental Health
2017English

Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab : One-Year Outcome in the EPILOG Trial

Circulation
Cardiovascular MedicinePhysiologyCardiology
1999English

Deaths Associated With Platelet Glycoprotein IIb/IIIa Inhibitor Treatment

Heart
2003English

Platelet Inhibition With an Antibody to Glycoprotein IIb/IIIa

Circulation
Cardiovascular MedicinePhysiologyCardiology
1989English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy